How to Manage Acute Toxicities After CAR-T Treatment?

By Blood Cancer Talks - Last Updated: July 19, 2023

Dr. Jain and the hosts discuss the research surrounding management of these toxicities, which can include cytokine release syndrome (CRS), immune effector cell-associated

What are the Controversies Surrounding MRD in Blood Cancers?

What are the Risk Factors, Treatment Options for Essential Thrombocythemia?

HMAs Are ‘Cornerstone’ in High-Risk MDS Treatment, Says Jamile Shammo, MD

Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL

Dr. Samer Al Hadidi Discusses CAR-T MM Data Presented at the FDA ODAC Meeting

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

How to Manage Acute Toxicities After CAR-T Treatment?

Related